Related Experiment Videos
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
Olivier Hanon1, Jean-Sébastien Vidal1, Sylvain Lehmann2
1Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Introduction:
Diagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD) process yields conflicting results. The objective of the study was to assess plasma levels of Aβ42 and Aβ40 in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and AD patients and to investigate relationships between peripheral and central biomarkers.
Methods:
One thousand forty participants (417 amnestic MCI, 122 nonamnestic MCI, and 501 AD) from the Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk multicenter prospective study with cognition, plasma, cerebrospinal fluid (CSF), and magnetic resonance imaging assessments were included.
Results:
Plasma Aβ1-42 and Aβ1-40 were lower in AD (36.9 [11.7] and 263 [80] pg/mL) than in amnestic MCI (38.2 [11.9] and 269 [68] pg/mL) than in nonamnestic MCI (39.7 [10.5] and 272 [52] pg/mL), respectively (P = .01 for overall difference between groups for Aβ1-42 and P = .04 for Aβ1-40). Globally, plasma Aβ1-42 correlated with age, Mini-Mental State Examination, and APOE ε4 allele. Plasma Aβ1-42 correlated with all CSF biomarkers in MCI but only with CSF Aβ42 in AD.
Discussion:
Plasma Aβ was associated with cognitive status and CSF biomarkers, suggesting the interest of plasma amyloid biomarkers for diagnosis purpose.
Insights
Plasma amyloid-beta (Aβ) levels show diagnostic potential for Alzheimer's disease (AD). Lower Aβ42 and Aβ40 in AD patients suggest their utility in diagnosing cognitive impairment.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Clinical Diagnostics
Background:
- Diagnostic relevance of plasma amyloid-beta (Aβ) for Alzheimer's disease (AD) remains debated.
- Conflicting results exist regarding the utility of plasma Aβ in AD diagnosis.
Purpose of the Study:
- To assess plasma Aβ42 and Aβ40 levels in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and AD patients.
- To investigate relationships between peripheral (plasma) and central (CSF) biomarkers.
Main Methods:
- Included 1040 participants (417 amnestic MCI, 122 nonamnestic MCI, 501 AD) from a multicenter study.
- Assessed cognition, plasma Aβ42/Aβ40, cerebrospinal fluid (CSF) biomarkers, and MRI.
Main Results:
- Plasma Aβ1-42 and Aβ1-40 were lower in AD patients compared to MCI groups (P=.01 and P=.04, respectively).
- Plasma Aβ1-42 correlated with age, Mini-Mental State Examination, and APOE ε4 allele.
- Plasma Aβ1-42 showed correlations with CSF biomarkers in MCI, and specifically with CSF Aβ42 in AD.
Conclusions:
- Plasma Aβ levels are associated with cognitive status and CSF biomarkers.
- Plasma amyloid biomarkers show promise for diagnostic applications in Alzheimer's disease.